//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
New Research Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial www.thelancet.com/journals/lan...
9d
www.thelancet.com
In both VACV-naive and VACV-experienced participants, BNT166a was well tolerated, with local and systemic reactogenicity events occurring more frequently after the second dose than the first. BNT166a ...
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial
The Lancet Infectious Diseases